Abstract:C/EBPβ overexpression exacerbates the pathologic progression of AD, primarily by promoting neuroinflammation and mediating transcriptional regulation of several disease‐associated proteins, such as δ‐secretase and APOE4. Additionally, C/EBPβ stimulates the upregulation of ANP32A and TRPC1, leading to elevated levels of phosphorylated Tau, while inhibiting the expression of FOXO, which is associated with genes involved in longevity. The in‐depth research of the pathway through which C/EBPβ regulates the development of AD also reveals multiple vicious cycle pathways between C/EBPβ overexpression and the pathological progression of AD. Background Alzheimer's disease (AD) is a neurodegenerative disorder distinguished by a swift cognitive deterioration accompanied by distinctive pathological hallmarks such as extracellular Aβ (β‐amyloid) peptides, neuronal neurofibrillary tangles (NFTs), sustained neuroinflammation, and synaptic degeneration. The elevated frequency of AD cases and its proclivity to manifest at a younger age present a pressing challenge in the quest for novel therapeutic interventions. Numerous investigations have substantiated the involvement of C/EBPβ in the progression of AD pathology, thus indicating its potential as a therapeutic target for AD treatment. Aims Several studies have demonstrated an elevation in the expression level of C/EBPβ among individuals afflicted with AD. Consequently, this review predominantly delves into the association between C/EBPβ expression and the pathological progression of Alzheimer's disease, elucidating its underlying molecular mechanism, and pointing out the possibility that C/EBPβ can be a new therapeutic target for AD. Methods A systematic literature search was performed across multiple databases, including PubMed, Google Scholar, and so on, utilizing predetermined keywords and MeSH terms, without temporal constraints. The inclusion criteria encompassed diverse study designs, such as experimental, case–control, and cohort studies, restricted to publications in the English language, while conference abstracts and unpublished sources were excluded. Results Overexpression of C/EBPβ exacerbates the pathological features of AD, primarily by promoting neuroinflammation and mediating the transcriptional regulation of key molecular pathways, including δ‐secretase, apolipoprotein E4 (APOE4), acidic leucine‐rich nuclear phosphoprotein‐32A (ANP32A), transient receptor potential channel 1 (TRPC1), and Forkhead BoxO (FOXO). Discussion The correlation between overexpression of C/EBPβ and the pathological development of AD, along with its molecular mechanisms, is evident. Investigating the pathways through which C/EBPβ regulates the development of AD reveals numerous multiple vicious cycle pathways exacerbating the pathological progression of the disease. Furthermore, the exacerbation of pathological progression due to C/EBPβ overexpression and its molecular mechanism is not limited to AD but also extends to other neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and multiple sclerosis (MS). Conclusion The overexpression of C/EBPβ accelerates the irreversible progression of AD pathophysiology. Additionally, C/EBPβ plays a crucial role in mediating multiple pathways linked to AD pathology, some of which engender vicious cycles, leading to the establishment of feedback mechanisms. To sum up, targeting C/EBPβ could hold promise as a therapeutic strategy not only for AD but also for other degenerative diseases.

CCAAT-Enhancer Binding Protein-beta (C/EBPP) Regulates Deltasecretase Expression, Mediating the Pathogenesis in Alzheimer's Disease

C/EBPβ Regulates Delta-Secretase Expression and Mediates Pathogenesis in Mouse Models of Alzheimer’s Disease

Spatiotemporal Activation Of The C/Ebp Beta/Delta-Secretase Axis Regulates The Pathogenesis Of Alzheimer'S Disease

C/EBPβ is a key transcription factor for APOE and preferentially mediates ApoE4 expression in Alzheimer’s disease

C/EBPβ: A transcription factor associated with the irreversible progression of Alzheimer's disease

Delta-secretase Cleaves Amyloid Precursor Protein and Regulates the Pathogenesis in Alzheimer's Disease

Deficiency in BDNF/TrkB Neurotrophic Activity Stimulates Δ-Secretase by Upregulating C/EBPβ in Alzheimer’s Disease

C/EBPβ/AEP signaling couples atherosclerosis to the pathogenesis of Alzheimer’s disease

Neuronal ApoE4 stimulates C/EBPβ activation, promoting Alzheimer’s disease pathology in a mouse model

Delta- and Beta-Secretases Crosstalk Amplifies the Amyloidogenic Pathway in Alzheimer's Disease

Delta- and beta- secretases crosstalk amplifies the amyloidogenic pathway in Alzheimer’s disease

Identification of Alzheimer's disease-associated rare coding variants in the ECE2 gene.

C/EBPβ/δ-secretase Signaling Mediates Parkinson's Disease Pathogenesis Via Regulating Transcription and Proteolytic Cleavage of Α-Synuclein and MAOB.

Neuronal C/EBPβ/AEP pathway shortens life span via selective GABAnergic neuronal degeneration by FOXO repression

A GPCR/secretase Complex Regulates Β- and Γ-Secretase Specificity for Aβ Production and Contributes to AD Pathogenesis

C/EBPβ/δ-secretase signaling mediates Parkinson’s disease pathogenesis via regulating transcription and proteolytic cleavage of α-synuclein and MAOB

C/EBPβ/AEP Signaling Drives Alzheimer's Disease Pathogenesis.

Cystatin C-Cathepsin B Axis Regulates Amyloid Beta Levels and Associated Neuronal Deficits in an Animal Model of Alzheimer's Disease

Delta-secretase Triggers Alzheimer's Disease Pathologies in Wild-Type Happ/hmapt Double Transgenic Mice.

Neurotrophic signaling deficiency exacerbates environmental risks for Alzheimer's disease pathogenesis

Dynamic alteration of neprilysin and endothelin-converting enzyme in age-dependent APPswe/PS1dE9 mouse model of Alzheimer's disease.